Skip to content
CovaSyn
Intro call

Use case

ICH M7 triage on the losartan example: two methods, one expert review

ICH M7 requires two (Q)SAR methods per impurity. On a Losartan worked example: 10 impurities classified in seconds, 5 probable mutagens identified, including the well-known azido impurity (AZBT). How both methods come together, and where the limits are.

CovaSyn team8 min read

All Articles
ICH M7 triage on the losartan example: two methods, one expert review

Key takeaways

  • ICH M7 requires two complementary (Q)SAR methods for every actual and potential impurity: one rule-based (structural alerts) and one statistical.
  • Our analysis runs both at once and classifies into ICH M7 classes 1 through 5.
  • On the Losartan worked example: 10 impurities assessed in seconds → 7 require control, of which 5 are probable mutagens (class 2), including the well-known genotoxic azido impurity.
  • The chemist focuses on the few flags instead of the entire list.
  • Context: (Q)SAR supports and documents the assessment, but does not replace expert review or, where required, a confirmatory Ames test.
ICH M7 triage Losartan: 10 impurities assessed, 7 control-required, 5 probable mutagens class 2
Fig. 1. Decision funnel. Of 10 assessed Losartan impurities, 7 require control under ICH M7 (class 1 through 3) and 5 are probable mutagens (class 2, both the structural-alert and the statistical method positive), including the genotoxic azido impurity. 3 are cleared (class 5, no control).

A trace impurity can block a submission

Mutagenic impurities are one of the most sensitive topics in drug approval. A single DNA-reactive trace compound, generated during synthesis or by degradation, can delay or stop a submission. The sartan class has demonstrated this publicly over the past years, first with nitrosamines, then with azido impurities.

ICH M7 is the regulatory answer. The guideline requires every actual and potential impurity to be assessed for mutagenic potential using two complementary (Q)SAR methods, one rule-based and one statistical. Done manually across dozens of synthesis intermediates and degradation products, this is slow, expert-dependent, and hard to document consistently.

We show on the active ingredient Losartan how our toxicity model prepares this assessment in seconds. The usual disclaimer up front: this is an illustrative impurity profile, and the predictions support the assessment; they do not replace the final expert judgement.

What ICH M7 requires: and how our toxicity model covers it

The core of ICH M7 is the requirement for two independent (Q)SAR approaches whose strengths complement each other. Our analysis runs both together:

1. Rule-based: structural alerts for DNA-reactive substructures (azides, alkyl halides, nitrosamines, reactive aldehydes). 2. Statistical: the deployed Ames mutagenicity model with a calibrated threshold, whose accuracy we report openly in the toxicity benchmark.

Both methods together give a preliminary classification that an expert then reviews. One point matters for the regulatory reading: under ICH M7 itself, class 2 requires a positive mutagenicity result. A prediction alone supports class 3 until an Ames test is available. Class 1 is controlled at a compound-specific limit, classes 2 and 3 at or below the TTC (Threshold of Toxicological Concern, 1.5 µg/day for lifetime exposure), except the cohort of concern such as N-nitroso compounds, for which compound-specific limits apply.

The result: from 10 to the few that matter

For the ten assessed Losartan impurities, the triage picture is clear: 7 of 10 require control (class 1 through 3), of which 5 are probable mutagens (preliminary class 2, where both methods agree), and 3 are cleared (class 5). Instead of treating all ten the same, the chemist can focus on the five class 2 flags. The full picture:

  • Azido impurity (AZBT): synthesis (azide/tetrazole route) · alert: azide · Ames stat. 0.89 (+) · class 2 · control required
  • Bromomethyl-biphenyltetrazole: synthesis intermediate · alkyl halide · 0.83 (+) · class 2 · control required
  • OTBN bromomethyl-cyanobiphenyl: synthesis intermediate · alkyl halide · 0.58 (+) · class 2 · control required
  • N-nitroso impurity (NDMA-type): synthesis (nitrosation risk) · nitrosamine · 0.72 (+) · class 2 · control required
  • Losartan aldehyde: degradation (oxidation) · aldehyde · 0.84 (+) · class 2 · control required
  • Losartan acid (EXP-3174): degradation / metabolite · no alert · 0.72 (+) · class 3 · control required
  • Desbutyl losartan: degradation · no alert · 0.58 (+) · class 3 · control required
  • 2-Butylimidazole intermediate: synthesis intermediate · no alert · 0.17 (−) · class 5 · no control
  • Biphenyl building block: synthesis intermediate · no alert · 0.07 (−) · class 5 · no control
  • Valeric acid (residual): synthesis side-product · no alert · 0.07 (−) · class 5 · no control

The azido impurity (AZBT) is, as expected, the most important hit, and both methods confirm it: structural alert and statistical model agree. The N-nitroso impurity needs its own look: it belongs to the cohort of concern, so the TTC does not apply and a compound-specific limit does.

In the evaluation workflow

The result is the classification as a structured table: directly documentation-ready, with the methodology trail that ICH M7 demands anyway.

The fine but decisive point: azide yes, tetrazole no

Sartans carry a tetrazole ring, a nitrogen-rich but in itself benign structure. Naive pattern matching easily goes astray here and alerts the whole scaffold. The craft of a robust structural alert is to hit the reactive azide of the AZBT impurity without falsely flagging the benign tetrazole ring of the active ingredient itself.

This is exactly the discrimination that makes automated screening usable in practice: otherwise the real warning drowns in false alarms.

Placed in context

(Q)SAR predictions support and document the assessment but do not replace expert review or, where required, a confirmatory Ames test. Every positive (class 1 through 3) needs expert evaluation. The statistical model is deliberately conservative and can flag the parent scaffold: here it pushes two actually benign Losartan degradants (EXP-3174, desbutyl losartan) into class 3, controlled at the TTC pending review. That is the intended ICH M7 posture and exactly where the expert review resolves the call.

Try it yourself

We run the same assessment on your own impurity list: both (Q)SAR methods, classified according to ICH M7, as a report your expert reviews and approves. → See example evaluations

FAQ

What does ICH M7 require for impurity assessment?

ICH M7 requires every actual and potential impurity to be assessed for mutagenic potential using two complementary (Q)SAR methods, one rule-based (structural alerts) and one statistical. Impurities in classes 1 through 3 must be controlled at or below the TTC (1.5 µg/day).

What does ICH M7 class 2 mean?

Class 2 designates a known mutagen with unknown carcinogenic potential, established by a positive bacterial mutagenicity assay; it is controlled at or below the TTC. An impurity with a structural alert but no mutagenicity data is class 3. When both (Q)SAR methods fire in automated assessment, our analysis reports this as a high-priority signal; regulatorily it remains class 3 until an Ames result is available.

Which (Q)SAR methods does ICH M7 require?

Two complementary ones: an expert rule-based method (structural alerts for DNA reactivity) and a statistical method (e.g. an Ames QSAR model). Our analysis runs both and combines them into a preliminary ICH M7 class for expert review.

Does (Q)SAR replace the Ames test?

No. (Q)SAR prioritizes and documents, and can complement or prepare the Ames test in many cases under ICH M7. Positives require expert evaluation and, where necessary, experimental confirmation.

Why is the azido impurity relevant for sartans?

On the tetrazole synthesis route of sartans, genotoxic azido impurities can form. They are structurally alerting (organic azide) and classified as control-required under ICH M7.

Methodology and data

ICH M7 dual assessment: expert rule-based structural alerts and a statistical Ames model. Worked example: Losartan, illustrative 10-impurity profile (synthesis intermediates + degradation products). TTC 1.5 µg/day for class 1 through 3. The accuracy of the underlying Ames model is documented in the toxicity benchmark.

Free PDF

Results you can rely on

Our beginner's guide for chemistry, pharma and biotech: how to tell an estimate from a calculation, seven questions to ask of every result and six questions to ask every provider. 8 pages.

Get the guide

Next step

Compute it instead of guessing.

30 minutes on Microsoft Teams with the CovaSyn team. If it is not a fit, we will say so.